CIDRAP newsletters options
The vaccine is 90% effective against hospitalization caused by all variants, including Delta, for at least 6 months.
"We've really started to see the infectious disease community embrace the idea of phage therapy."
Though cases declined overall, the number of pediatric cases remains at high levels that have persisted since the school year started.
An analysis determines that the approach would be more cost-effective in the US than in China or India.
Though the continent lags well behind the rest of the world due to persistent supply inequity, it is making modest progress.
A national ambulatory antibiotic stewardship program was associated with declines in overall and acute respiratory infection (ARI)-related prescribing during the COVID-19 pandemic, US researchers reported last week at ID Week 2021.
COVID-19 variants of concern (VOCs), especially the Delta (B1617.2) variant, are more virulent than the wild type, according to an Ontario-based study published in CMAJ yesterday. The cohort included 212,326 cases of non-VOCs (22.4%) and VOCs with the N501Y mutation (76.7%), such as Alpha (B117), Beta (B1351), Gamma (P1), and Delta.
Also, the persistence of depressive symptoms for more than 1 year was greater than after the Sep 11 attacks.
Though the Delta surge appears to be ebbing, several states are still experiencing overcrowded hospitals.
In other global developments, New Zealand announces a plan to loosen restrictions as Delta cases pop up in new parts of Australia.
Report says the supply chain needs more assessment, and mitigation steps must be fully developed.
Diagnostics company OpGen announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market a new rapid molecular diagnostic tool that could aid in treating antibiotic-resistant or non-susceptible infections.
Reinfection from SARS-CoV-2 under endemic conditions will most likely occur at a median of 16 months, according to a modeling study published late last week in The Lancet Microbe.
Two studies assessed COVID-19 vaccine hesitancy in minorities and toward specific vaccine brands.
Also, Merck says its investigational oral antiviral drug reduces the risk of COVID-19 death by 50%.
One study highlights the fallout of unstable housing on Americans' mental and physical health.
New antimicrobials to treat severe bacterial and fungal infections were among the drugs that the World Health Organization (WHO) included in its new Essential Medicines list, which is updated annually and serves as its recommended list of medicines that every health system should have.
Hospitalized COVID-19 patients who were treated with remdesivir within 2 days of admission had lower mortality rates than their matched cohort, according to a study today in Clinical Infectious Diseases. The observational cohort consisted of US adults hospitalized with COVID-19 from August to November 2020; 28,855 received remdesivir and 16,887 did not.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
The 10-year plan starts today and gives recommendations for a range of scientific disciplines to better address seasonal flu and prepare for the next flu pandemic.
